Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02826577 · ClinicalTrials.gov registry record · Phase 2
Effects of Pregnenolone on Perceived Social Isolation
A Phase 2 study, sponsored by University of Chicago.
- Terminated
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT02826577 is a Phase 2 study that was terminated before completion, run by University of Chicago. The registered enrollment target is 34 participants.
The verdict
NCT02826577, a Phase 2 study, was terminated before completion, sponsored by University of Chicago.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
No studies to date have examined the effects of pregnenolone on hypervigilance for social threat in individuals with perceived social isolation (PSI). We therefore are conducting a double-blind randomized research study combining three validated behavioral paradigms on social threat attention, perception of others, and emotion regulation with high-density electrical neuroimaging to probe the neuro-circuitry of social threat processing in young adults high in perceived social isolation two hours after the oral administration of 175mg pregnenolone (N = 24), 400mg of pregnenolone (N = 24), or placebo (N = 24). Such research has the potential to yield important insights into the neurobehavioral mechanisms of pregnenolone on hypervigilance for social threat and perception of others--- a first key step toward the development of adjunctive pregnenolone therapy in individuals with PSI.
Interventions
- DRUG Placebo
- DRUG Pregnenolone 175mg
- DRUG Pregnenolone 400mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2017-05-01 |
| Est. Completion | 2022-12-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02826577
The ClinicalTrials.gov registry entry for NCT02826577 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02826577 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02826577 about?
NCT02826577 is a clinical study titled "Effects of Pregnenolone on Perceived Social Isolation". No studies to date have examined the effects of pregnenolone on hypervigilance for social threat in individuals with perceived social isolation (PSI). We therefore are conducting a double-blind randomized research study combining three validated behavioral paradigms on social threat attention, perce...
What is the current status of trial NCT02826577?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2017-05-01. Estimated completion is 2022-12-21.
What interventions are being tested in trial NCT02826577?
The interventions under investigation include: Placebo (DRUG), Pregnenolone 175mg (DRUG), Pregnenolone 400mg (DRUG).
Who is sponsoring clinical trial NCT02826577?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.